What are the contraindications for febuxostat?

Contraindications for Febuxostat

Febuxostat is absolutely contraindicated in patients receiving concomitant treatment with azathioprine or mercaptopurine, as this combination can result in life-threatening myelosuppression. 1

Absolute Contraindication

Thiopurine Immunosuppressants

• Do not use febuxostat with azathioprine or mercaptopurine - this is a black box contraindication
• The mechanism involves xanthine oxidase inhibition increasing active metabolite concentrations of these drugs, leading to severe bone marrow suppression
• In 19 documented cases, the median time to myelosuppressive events was only 1.6 months after starting the combination
• 16 of these cases required hospitalization and 15 needed blood product transfusions 1
• Current FDA labeling explicitly contraindicates this combination 2

Relative Contraindications and Major Warnings

Cardiovascular Disease History

While not an absolute contraindication, febuxostat carries significant cardiovascular mortality concerns in patients with established CVD:

• The FDA-mandated CARES trial demonstrated increased cardiovascular death and all-cause mortality with febuxostat compared to allopurinol in patients with CVD 3
• The 2020 ACR guidelines conditionally recommend switching to an alternative ULT (preferably allopurinol) for patients taking febuxostat who have a history of CVD or develop a new cardiovascular event 4, 3
• Recent real-world data (2026) confirms modestly increased all-cause mortality (HR: 1.125) in CVD patients on febuxostat versus allopurinol 5
• Shared decision-making is essential - discuss the cardiovascular risks explicitly with patients who have coronary artery disease, heart failure, or prior MI/stroke

Severe Renal Impairment (Stage 4-5 CKD)

• Not an absolute contraindication, but use with caution
• The 2012 ACR guidelines note lack of published safety data for febuxostat in stage 4 or worse CKD 2
• Interestingly, patients with CKD stages 4-5 actually require lower doses to achieve target uric acid levels (mean 50 mg vs 60 mg in normal renal function) 6
• Pharmacokinetic modeling shows AUC increases 2.27-fold in severe kidney impairment and 2.65-fold in ESRD 7

Clinical Algorithm for Febuxostat Use

Step 1: Screen for absolute contraindication

• Is patient on azathioprine or mercaptopurine? → Do not prescribe febuxostat

Step 2: Assess cardiovascular risk

• Does patient have established CVD (prior MI, stroke, heart failure, coronary disease)? → Strongly prefer allopurinol over febuxostat 4, 3
• If febuxostat must be used in CVD patient, document detailed discussion of mortality risks

Step 3: Evaluate renal function

• CKD stages 4-5 (eGFR <30 mL/min)? → Consider allopurinol first-line, but febuxostat can be used with dose adjustment if needed 8

Step 4: Consider alternative indications

• Febuxostat is appropriate when allopurinol is contraindicated, not tolerated, or fails to achieve target uric acid at maximum appropriate dosing 8, 9

Key Pitfalls to Avoid

• Never combine febuxostat with allopurinol - the 2012 ACR guidelines explicitly state these should not be used together 2
• Do not assume febuxostat is "safer" than allopurinol in renal disease - while no dose adjustment is required, the cardiovascular mortality signal makes allopurinol preferable as first-line therapy even in CKD 4
• Remember that febuxostat is not recommended as first-line therapy for any patient population - allopurinol remains the strongly recommended initial choice 4